Alpha 1 Antitrypsin Deficiency Treatment Market to Rise at 10.1% CAGR during Forecast Period: TMR Study WILMINGTON, DE | ACCESSWIRE | September 29, 2022 | Transparency Market Research Inc. - In 2018, the research report also states that the revenue of alpha 1 antitrypsin deficiency treatment market was estimated at US$ 1.4 Bn. According to the TMR report, alpha 1 antitrypsin deficiency treatment market size is likely to expand at 10.1% CAGR during the forecast period, from 2019 to 2027. As per alpha 1 antitrypsin deficiency treatment market demand analysis, a major factor supporting demand is the rising high incidence and prevalence of several respiratory disorders. Additionally, the general population is becoming more aware of alpha-1 antitrypsin insufficiency and available treatments. The World Health Organization estimates that 65 million individuals worldwide have COPD, also known as chronic obstructive lung disease. According to the report, the same illness kills almost 3 million individuals yearly across the globe. Additionally, in the upcoming years, the demand for alpha 1 antitrypsin deficiency treatments are expected to be fueled by increasing government activities to produce and sell blood and plasma products.